Femasys shares rise 10.68% premarket after receiving CE Mark certification for FemBloc® non-surgical birth control system.

Femasys Inc. surged 10.68% in premarket trading following the announcement that it received CE Mark certification for its FemBloc® System, a non-surgical permanent birth control solution. The regulatory approval, a critical milestone for medical devices in the European Union, enables the company to market the product in EU markets, signaling potential revenue growth and market expansion. The certification underscores Femasys' progress in advancing its pipeline and aligning with global regulatory standards, likely driving investor optimism ahead of the trading session.